Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab multiple-dose study in healthy adults
NCT05894148Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of genakumab in interstitial lung disease (ILD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Frequency of adverse events up to 20 weeks. Started Mar 2023; status: completed.
02
Drugs
genakumab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05894148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894148.